User menu

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Bibliographic reference Baselga, José ; Im, Seock-Ah ; Iwata, Hiroji ; Cortés, Javier ; De Laurentiis, Michele ; et. al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.. In: The Lancet Oncology, Vol. 18, no.7, p. 904-916 (2017)
Permanent URL http://hdl.handle.net/2078.1/187803